Is Arcus Biosciences, Inc. (RCUS) a Buy, Sell, or Hold?
Arcus Biosciences, Inc.
NYSE:RCUS
$28.02 USD
-$0.31 (-1.09%)
- Volume
- 565.74K
- Average Volume
- 1.33M
- Market Capitalization
- $2.82B
- P/E Ratio
- -8.85
- Dividend Yield
- 0.00%
- Price Target
- $29.00
- Year High
- $31.74
- Year Low
- $8.84
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.04
Industry, Sector & symbol
| Stock Exchange | NYSE |
| CEO | Terry J. Rosen |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | RCUS |
| CUSIP | 03969F109 |
| CIK | 0001724521 |
| Web | https://arcusbio.com |
| Phone | 510 694 6200 |
| Currency | USD |
| Employees | 601 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.22 |
| Payout Ratio | 0.00 |
| Current Ratio | 4.04 |
| Quick Ratio | 4.04 |
| Cash Ratio | 0.96 |
Sales & Book Value
| Annual Sales | $247M |
| Price / Sales | 11.95 |
| Cash Flow | -3.90 |
| Price / Cash Flow | -5.77 |
| Price / Book | 6.71 |
Price Target and Rating
| Average Stock Price Forecast | $29.00 |
| High Stock Price Forecast | $47.00 |
| Low Stock Price Forecast | $22.00 |
| Forecast Upside/Downside | -3.38% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 18 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-3.29 |
| Trailing P/E Ratio | -8.85 |
| PEG Ratio | -0.39 |
| P/E Growth | -0.39 |
| Net Income | $-353M |
| Net Margin | -156.36% |
| Pretax Margin | -156.36% |
| Return on Equity | -68.97% |
| Return on Assets | -37.01% |
Financials Score
| AltmanZ Score | 1.20 |
| Piotroski Score | 1.00 |
| Working Capital | 635M |
| Total Assets | 997M |
| Ebit | -339M |
| Market Cap | 2.83B |
| Total Liabilities | 473M |
Poll Results
About Arcus Biosciences, Inc. (NYSE:RCUS) Stock
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clini ... cal trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Run
2026-07-13 19:09:17
This sale was executed under a Rule 10b5-1 plan following a 203% one-year surge.
Arcus Biosciences Announces New Employment Inducement Grants
2026-07-09 16:35:00
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted five new employee options to purchase a total of 16,060 shares of the Company's common stock at an exercise price per share of $30.26, which was the.
2026-07-01 11:00:00
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a publication in Nature describing new research from the ARC-20 study. The publication evaluated casdatifan, an investigational, small-molecule HIF-2a inhibitor, as a monotherapy in patients with metastatic clear cell rena.
Arcus Biosciences Announces New Employment Inducement Grants
2026-06-24 16:35:00
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted two new employees options to purchase a total of 18,400 shares of the Company's common stock at an exercise price per share of $28.18, which was the.
2026-06-09 21:02:10
Arcus Biosciences, Inc. (RCUS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Arcus Biosciences Announces New Employment Inducement Grants
2026-06-09 16:35:00
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted one new employee options to purchase a total of 2,850 shares of the Company's common stock at an exercise price per share of $23.32, which was the.
Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study
2026-06-04 12:55:34
Arcus Biosciences teams up with Bristol Myers Squibb to test casdatifan combinations in kidney cancer, expanding its ccRCC development strategy.
2026-06-03 08:00:00
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”). Under the agreement, Arcus will supply casdatifan, the company's investigational small-molecule HIF-2a inhibitor, to be eval.
Frequently Asked Questions
-
What is the current Arcus Biosciences, Inc. (RCUS) stock price?
-
Arcus Biosciences, Inc.(NYSE:RCUS) stock price is $28.02 in the last trading session. During the trading session, RCUS stock reached the peak price of $31.735 while $8.84 was the lowest point it dropped to. The percentage change in RCUS stock occurred in the recent session was --1.09% while the dollar amount for the price change in RCUS stock was -$-0.31.
-
RCUS's industry and sector of operation?
-
The NYSE listed RCUS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of RCUS?
-
Richard A. Markus | Chief Medical Officer
Alexander Azoy | Chief Accounting Officer
Holli Kolkey | Vice President of Corporate Communications
Carolyn C. Tang | General Counsel & Corporate Secretary
Jennifer A. Jarrett | Advisor -
How many employees does RCUS have?
-
Number of RCUS employees currently stands at 601. RCUS operates from 3928 Point Eden Way, Hayward, CA 94545, US.
-
Link for RCUS official website?
-
Official Website of RCUS is: https://arcusbio.com
-
How do I contact RCUS?
-
RCUS could be contacted at phone #510 694 6200 and can also be accessed through its website. RCUS operates from 3928 Point Eden Way, Hayward, CA 94545, US.
-
How many shares of RCUS are traded daily?
-
The average number of RCUS shares traded daily for last 3 months was 1.33M.
-
What is the market cap of RCUS currently?
-
The market value of RCUS currently stands at $2.82B with its latest stock price at $28.02